Evidence review

ARA-290 for Carpal Tunnel: Human Trial Data on Nerve Symptoms and Fiber Density

#peptide#topic
bundle · json · system map · manifest

Every copy includes §SELF — what this is, proof chain, and links to every other feature. No context required.

§SELF — this page explains the system
## §SELF — miscsubjects (paste without context)

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `human_page` — **Human article page**
Rendered article with claims, sources, copy widgets, ask prompts.
- **article slug:** `ara-290-carpal-tunnel`
- **contains:** rendered article, copy widgets, claims, sources, ask prompts
- **how to use:** Use Copy for LLM or Copy system map — both paste without context.
- **read:** https://miscsubjects.com/a/ara-290-carpal-tunnel

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/ara-290-carpal-tunnel/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **bundle** — Paste-ready package: body + claims + sources + voxels + provenance + manifest + constitution. · https://miscsubjects.com/api/articles/ara-290-carpal-tunnel/bundle?format=markdown
- **ask** — Answer only from topology; creates question_node with gaps and ingest_hint. · https://miscsubjects.com/api/articles/ara-290-carpal-tunnel/prompts
- **topology** — Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER. · https://miscsubjects.com/api/articles/ara-290-carpal-tunnel/topology

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

*Not medical advice. Tier-honest. Cite claim/source ids.*

What's breaking down if you have Carpal tunnel syndrome

The body is always doing two things at once: breaking down (degeneration) and building back (regeneration). A condition persists when breakdown outruns repair. Most drugs used for symptoms suppress a signal (pain, acid, anxiety, inflammation) without fixing the tissue that caused the signal. Peptides in this ledger are studied for repair pathways: new blood vessels, repair-cell migration, nerve regrowth, gut lining, neural connections. This article maps one compound through that frame — what it is, how it is proposed to work, what evidence exists, and what people report.

This topic: ARA-290 is studied for nerve repair — especially small-fiber and neuropathy models. Nerves degenerate when damaged; ARA-290 research asks whether innervation can regrow.

Why ARA-290 might help you

  1. You are reading about Carpal tunnel syndrome — what breaks down matters before any compound name.
  2. What keeps failing: Nerve compression, small-fiber loss, neuropathic pain signaling without tissue repair.
  3. What ARA-290 is studied to do: Studied for nerve repair and small-fiber regeneration in neuropathy models.
  4. Therefore for you: If that layer is part of your problem, ARA-290 is discussed because it targets repair (nerve / innervation) — not because it masks pain.

How these fit together

Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.

  • ARA-290 → nerve / innervation

What the evidence actually shows

This is a count of what is in this ledger — not a claim about all research worldwide.

  • Scientific sources catalogued (PubMed, trials, reviews): 3
  • Claims tagged human evidence: 8
  • Claims tagged preclinical (animal/lab): 1
  • Claims tagged anecdotal: 9
  • Reddit posts catalogued: 5
  • X posts catalogued: 2
  • Other anecdote sources (YouTube, Instagram, etc.): 0
  • Total sources in chain: 10

Quantified confidence (this ledger): 0.95 / 1.00 — moderate — human claims present in ledger

Formula: human claims×0.12 + preclinical×0.04 + anecdote×0.015 + studies (capped). This is not clinical certainty — it measures how much graded evidence is catalogued here.

What scientists say

ARA 290, a Nonerythropoietic Peptide Engineered from Erythropoietin, Improves Metabolic Control and Neuropathic Symptoms in Patients with Type 2 Diabetes (source s1)

Phase 2 RCT: 4 mg SC daily ×28 d improved symptoms and CNFD in diabetic neuropathy subgroup.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

Targeting the innate repair receptor to treat neuropathy (source s2)

Reviews preclinical rat data on neuropathic pain relief.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

ARA290, an alternative of erythropoietin, inhibits activation of NLRP3 inflammasome in schwann cells after sciatic nerve injury (source s10)

2025 preclinical study showing ARA290 (cibinetide) inhibits NLRP3 inflammasome in Schwann cells post-sciatic nerve crush injury in rats, promoting nerve repair and regeneration via reduced inflammation and ROS.

Evidence type: Animal or lab work — shows mechanism or early signal, not proof in people.

What people say on Reddit

Anybody try ARA-290 peptide for nerve damage? — Reddit, r/Biohackers (source s3)

User reports no benefit for tarsal tunnel (compression neuropathy analogous to carpal tunnel) but positive axonal repair in another nerve injury after 2 months at 5mg/day.

Anybody try ARA-290 peptide for nerve damage? — Reddit, r/Biohackers (source s4)

Positive user experience repairing axonal nerve damage with ARA-290; notes it did not help compression-related tarsal tunnel pain.

Peptide ARA-290 : r/neuropathy — Reddit, r/neuropathy (source s5)

Multiple users report bad outcomes with ARA-290 causing painful nerve flares/pins and needles, leading them to stop treatment early despite trying titration for neuropathy (one mentions autoimmune-related sensitivity).

ARA-290 Disc Herniaton & Nerve Pain : r/neuropathy — Reddit, r/neuropathy (source s6)

User with confirmed carpal tunnel (via EMG) and other neuropathy planning 28+ day ARA-290 cycle at 3-6mg/day for nerve pain, no outcome reported yet but notes interest in honest results.

Anyone try ARA290 peptide for this tinnitus? : r/tinnitus — Reddit, r/tinnitus (source s7)

Post discusses ARA-290 as potential for nerve regeneration including carpal tunnel syndrome, seeking user experiences (no detailed personal outcomes in snippet).

What people say on X

X post by @I_Research_Pept — X (source s8)

User seeking experiences with ARA-290 specifically for carpal tunnel; reports bad batch purchased but no treatment outcome yet.

X post by @SEpilogueG — X (source s9)

User with severe work-induced carpal tunnel inquiring about purchasing ARA-290 (no outcome reported).

What we do not know

  1. There is a lack of large randomized human trials for ARA-290's common marketed uses, including its application in carpal tunnel syndrome.
  2. It is unknown whether the effects of ARA-290 on nerve symptoms and fiber density in patients with neuropathy can be directly extrapolated to carpal tunnel syndrome, as no specific studies have been conducted for this condition.
  3. The long-term efficacy and safety of ARA-290 for chronic neuropathic conditions, such as carpal tunnel syndrome, are not established due to the limited duration of available human trial data.

Safety and limits

  1. Hash-chained sources verify integrity, not clinical truth. Evidence mix is predominantly preclinical and anecdotal; human data are sparse. No dosing, protocol, or treatment recommendations — catalogue only.

Peptide components (collapsible embeds)

ARA-290: Nerve Repair Peptide · nerve / innervation · ara-290
{
  "peptide": "ara-290",
  "regenerative_layer": "nerve / innervation",
  "targets_this_degeneration": "Nerve compression, small-fiber loss, neuropathic pain signaling without tissue repair.",
  "proposed_regeneration": "Studied for nerve repair and small-fiber regeneration in neuropathy models.",
  "evidence_in_ledger": {
    "human_claims": 13,
    "preclinical_claims": 1,
    "anecdote_claims": 45,
    "studies_catalogued": 21
  },
  "confidence_0_to_1": 0.95,
  "confidence_label": "moderate (human data present)",
  "full_article": "https://miscsubjects.com/a/ara-290"
}

Regeneration vs degeneration — where this fits Nerves break down after injury or disease. Small fiber neuropathy is one case where breakdown outruns repair. Most drugs used for neuropathy reduce pain signals without changing nerve structure. ARA-290 is studied for the repair side: whether damaged small nerves can regro…

Full ara-290 article →

---

Not medical advice. Counts and quotes are from this article's hash-chained ledger. Anecdote = real reports, not proof. Animal studies ≠ human proof.

Carpal tunnel · condition map

Evidence map

Hover a node — its path lights up. Click to open the article.

Full map →
JumpARA-290: Nerve Repair Peptide · 13 humanARA-290 for Diabetic Neuropathy: Human Trial Data · 12 humanARA-290 × Stimulant-driven insomniaBenzo Withdrawal
Evidence · 10 sources · swipe →chain 3e42ffedd1ae · verify chain · provenance
1 / 10
Evidence ledger 25 · tier-ranked · API
mechanistic
Hash-chained sources verify integrity, not clinical truth. Evidence mix is predominantly preclinical and anecdotal; human data are sparse. No dosing, protocol, or treatment recommendations — catalogue only.
human
No human trials of ARA-290 in carpal tunnel syndrome exist.
mechanistic
While the claim states that no human trials of ARA-290 in carpal tunnel syndrome exist, this contradicts the information provided in sourced claims c1 and c2, which describe a phase 2 trial involving ARA-290 and human neuropathy.
mechanistic
The claim that no human trials of ARA-290 in carpal tunnel syndrome exist is contradicted by sourced claims c1 and c2, which describe a phase 2 trial involving ARA-290 and human neuropathy.
system
Combinatorial mapping (transparent): ara-290 vs carpal-tunnel — regen=0.59, degen=0.75, Δ=-0.16. Method: layer_relevance(0.60) × evidence_factor(0.85); catalog.degen_score for Carpal tunnel syndrome.
18 more ranked claims
system0.35
ARA-290 for Carpal Tunnel: Human Trial Data on Nerve Symptoms and Fiber Density is catalogued in this miscsubjects ledger as a tier-honest evidence graph (claims + hash-chained sources). This page summarizes what is claimed in the literature and online about the topic — not clinical recommendations.
miscsubjects protocol
Required constitution slot: what_it_is
anecdotal0.30
User seeking experiences with ARA-290 specifically for carpal tunnel; reports bad batch purchased but no treatment outcome yet.
grok/grok-4.3
Materialized from orphan source s8 by ledger repair
sources: s8
anecdotal0.30
User with severe work-induced carpal tunnel inquiring about purchasing ARA-290 (no outcome reported).
grok/grok-4.3
Materialized from orphan source s9 by ledger repair
sources: s9
anecdotal0.30
User reports from anecdotal sources vary widely in their experiences with ARA-290 for carpal tunnel syndrome, with some reporting no benefit and others noting positive effects on nerve repair but not on compression-related pain.
kimi/moonshot-v1-8k
This claim aggregates the anecdotal claims made by various users regarding their experiences with ARA-290 for carpal tunnel syndrome, which are supported by the sourced Reddit posts and other anecdotal sources listed in the topology.
sources: s3, s4, s5, s6, s7, s8, s9
anecdotal0.30
Anecdotal reports of ARA-290's effects on carpal tunnel syndrome are limited and vary widely, with no clear consensus on its efficacy.
kimi/moonshot-v1-8k
This claim aggregates the anecdotal claims made by various users regarding their experiences with ARA-290 for carpal tunnel syndrome, which are supported by the sourced Reddit posts and other anecdotal sources listed in the topology, providing a clearer picture of who claims what.
sources: s3, s4, s5, s6, s7, s8, s9
human0.22downweightedlow confidence
In a phase 2 trial of T2D patients with neuropathy, 4 mg ARA-290 daily for 28 days improved PainDetect scores significantly vs placebo.
grok/4.3-populate
Direct evidence of symptom improvement in human neuropathy trial
sources: s1
human0.22low confidence
Subgroup with low baseline corneal nerve density showed significant CNFD increase after ARA-290 vs placebo.
grok/4.3-populate
Evidence of possible nerve fiber regrowth in humans
sources: s1
human0.22
Not medical advice. Tier-honest research catalogue only — consult qualified healthcare professionals for personal health decisions.
system/protocol
Required constitution slot: disclaimer
human0.22low confidence
There is a lack of large randomized human trials for ARA-290's common marketed uses, including its application in carpal tunnel syndrome.
kimi/moonshot-v1-8k
This claim identifies a specific gap in the evidence regarding the use of ARA-290 for carpal tunnel syndrome, which is supported by the sourced PubMed article that discusses a trial but does not provide data on large randomized trials for common uses.
sources: s1
human0.22low confidence
It is unknown whether the effects of ARA-290 on nerve symptoms and fiber density in patients with neuropathy can be directly extrapolated to carpal tunnel syndrome, as no specific studies have been conducted for this condition.
kimi/moonshot-v1-8k
This claim addresses a specific gap in knowledge regarding the applicability of ARA-290's effects from neuropathy studies to carpal tunnel syndrome, which is not covered by existing claims.
sources: s1
human0.22low confidence
ARA-290 is a nonerythropoietic peptide derived from erythropoietin, proposed to act by targeting the innate repair receptor to treat neuropathy.
gemini-collaborator
Provides fundamental information about the nature and proposed mechanism of action of ARA-290, which is currently missing from the ledger.
sources: s1, s2
human0.22low confidence
The long-term efficacy and safety of ARA-290 for chronic neuropathic conditions, such as carpal tunnel syndrome, are not established due to the limited duration of available human trial data.
gemini-collaborator
Addresses a critical gap in knowledge regarding the sustained benefits and potential risks of ARA-290 for chronic conditions, which is not explicitly covered by existing claims. Source s1 describes a 28-day trial, implying longer-term data is not presented.
sources: s1
preclinical0.22
2025 preclinical study showing ARA290 (cibinetide) inhibits NLRP3 inflammasome in Schwann cells post-sciatic nerve crush injury in rats, promoting nerve repair and regeneration via reduced inflammation and ROS.
grok-4.3
Materialized from orphan source s10 by ledger repair
sources: s10
anecdotal0.22low confidence
User reports no benefit for tarsal tunnel (compression neuropathy analogous to carpal tunnel) but positive axonal repair in another nerve injury after 2 months at 5mg/day.
grok/grok-4.3
Materialized from orphan source s3 by ledger repair
sources: s3
anecdotal0.22
Positive user experience repairing axonal nerve damage with ARA-290; notes it did not help compression-related tarsal tunnel pain.
grok/grok-4.3
Materialized from orphan source s4 by ledger repair
sources: s4
anecdotal0.22
Multiple users report bad outcomes with ARA-290 causing painful nerve flares/pins and needles, leading them to stop treatment early despite trying titration for neuropathy (one mentions autoimmune-related sensitivity).
grok/grok-4.3
Materialized from orphan source s5 by ledger repair
sources: s5
anecdotal0.22low confidence
User with confirmed carpal tunnel (via EMG) and other neuropathy planning 28+ day ARA-290 cycle at 3-6mg/day for nerve pain, no outcome reported yet but notes interest in honest results.
grok/grok-4.3
Materialized from orphan source s6 by ledger repair
sources: s6
anecdotal0.22low confidence
Post discusses ARA-290 as potential for nerve regeneration including carpal tunnel syndrome, seeking user experiences (no detailed personal outcomes in snippet).
grok/grok-4.3
Materialized from orphan source s7 by ledger repair
sources: s7
Low-confidence / auto-generated 2
speculative0.12low confidence
Rat models show ARA-290 produces long-lasting neuropathic pain relief via repair pathways.
grok/4.3-populate
Separates animal from human evidence
sources: s2
speculative0.10
Commercial vendors and clinics market this compound (0 commercial/clinic sources catalogued) — marketing material, not evidence.
commercial vendors
Collapsed 5 duplicate marketing claims
Model swipes · 15 from 6 models · swipe →verify
1 / 15
grok/grok-4.3writer
redraft2026-06-29 08:54
ARA-290 for Carpal Tunnel: Human Trial Data on Nerve Symptoms and Fiber Density · 4 claims · 2 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: PEPTIDE DEFINITIONS (use for mechanism accuracy; no medical claims):
BPC-157 — Body Protection Compound. Derived from gastric juice protein. Builds new blood vessels into damaged tissue locally. 100+ animal/cell studies (tendon, gut, muscle, bone, nerve).
TB-500 — Synthetic Thymosin Beta-4. Moves repair cells to damage; clears stuck inflammation systemically. Production drops ~60% by age 60.
ARA-290 — Nerve repair peptide with human clinical trial data. Regrows damaged nerves; does not mask nerve pain.
Semax — Brain peptide; upregulates BDNF for neuroprotection and cognitive recovery.
Selank — Anxiolytic peptide; reduces anxiety without sedation or addiction (non-benzodiazepine pathway).
PT-141 — Sexual function; brain-level arousal signaling (FDA-approved mechanism as Vyleesi).
DSIP — Del
it output
{
  "slug": "ara-290-carpal-tunnel",
  "title": "ARA-290 for Carpal Tunnel: Human Trial Data on Nerve Symptoms and Fiber Density",
  "body": "## Background on Carpal Tunnel and Persistent Nerve Issues\n\nCarpal tunnel syndrome involves compression of the median nerve at the wrist. Even after surgical release, some patients experience ongoing sensory symptoms or incomplete functional recovery due to prior axonal damage.\n\n## ARA-290 Mechanism\n\nARA-290 is an 11-amino-acid peptide derived from erythropoietin that selectively activates the innate repair receptor (IRR). This activates anti-inflammatory and tissue-repair pathways without erythropoietic effects (human trial data; mechanistic).\n\n## Human Clinical Data\n\nIn a phase 2 double-blind placebo-controlled trial of 22 adults with type 2 diabetes and painful neuropathy, 4 mg ARA-290 subcutaneously daily for 28 days improved PainDetect neuropathic symptom scores by 3.3 points vs 1.1 for placebo at day 28 (p=0.037); improvement increased to 4.2 points at day 56 (human). Subgroup analysis of subjects with reduced corneal nerve fiber density showed +2.6 fibers/mm² increase vs +0.7 for placebo (p=0.02) (human).\n\nIn sarcoidosis-associated small-fiber neuropathy trials, ARA-290 improved neuropathic and autonomic symptoms and quality-of-life scores; one trial showed increased corneal nerve fiber abundance after 28 days (human).\
1e822a0ea39b9a54
grok-4.3source_hunt
sources2026-06-29 12:01
2 source(s) added · 2 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-290-carpal-tunnel
it output
2 source(s) added
3dd60d65206444ad
grok-4.3source_hunt
sources2026-06-29 12:06
5 source(s) added · 5 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-290-carpal-tunnel
it output
5 source(s) added
bfd24232c6022e40
system/audit-repairclaim_post
claim2026-06-29 12:46
claim
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-290-carpal-tunnel
it output
{"materialized":0,"before":[],"after":[]}
28a70b25582e8a7b
system/audit-repairclaim_post
claim2026-06-29 12:46
claim
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-290-carpal-tunnel
it output
{"materialized":0,"before":[],"after":[]}
99c952b90476f399
system/audit-repairclaim_post
claim2026-06-29 12:46
claim
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-290-carpal-tunnel
it output
{"materialized":0,"before":[],"after":[]}
4b9de1282bddadc0
system/audit-repairclaim_post
claim2026-06-29 12:46
claim
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-290-carpal-tunnel
it output
{"materialized":0,"before":[],"after":[]}
97ea47bbf6949344
system/audit-repairclaim_post
claim2026-06-29 12:46
claim
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-290-carpal-tunnel
it output
{"materialized":0,"before":[],"after":[]}
f2c3669673657dca
kimi/moonshot-v1-8kcollaborator
collaborate2026-06-29 13:21
collaborate
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-290-carpal-tunnel
it output
I am adding explicit gaps in knowledge regarding ARA-290 for carpal tunnel syndrome, as well as identifying who claims what from anecdotes that are not currently attributed to specific sources.
9bcc11b2380eaffd
kimi/moonshot-v1-8kcollaborator
collaborate2026-06-29 13:22
collaborate
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-290-carpal-tunnel
it output
I am adding explicit gaps in knowledge (what_is_unknown) and identifying who claims what from anecdotes where this information is missing, as per the instructions.
a1b1d6d38fff3813
gemini/gemini-2.5-flashcollaborator
collaborate2026-06-29 14:49
collaborate
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-290-carpal-tunnel
it output
Added claims to clarify the mechanistic basis of ARA-290 and highlight the unknown long-term efficacy and safety in humans. Challenged an incorrect tier classification for a human clinical trial claim to improve ledger accuracy, as I am Gemini, not Grok.
004022c0d1a54863
grok/grok-4.3editor
synthesize_body2026-06-29 14:50
synthesize_body
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-290-carpal-tunnel
it output
## Regeneration vs degeneration — where this fits
Nerves can break down after compression or injury. Carpal tunnel involves pressure on the median nerve. If breakdown outruns repair, symptoms persist. ARA-290 is studied for nerve repair pathways rather than symptom suppression.

## What it is
ARA-290 is a peptide derived from erythropoietin. It does not raise red blood cells. It targets the innate repair receptor.

## How it works
Step 1: The peptide binds the innate repair receptor.  
Step 2: Binding activates repair signals in nerve tissue.  
Step 3: Signals support nerve fiber maintenance and symptom change in some models.

## Why it would work (logic chain)
If the receptor controls repair, then binding it may increase nerve fiber density. If density increases, then symptoms tied to low density may decrease. If symptoms decrease without addressing mechanical compression, then benefit may stay limited in entrapment cases.

## Why people take it
People take it when they seek nerve repair options beyond standard symptom relief. Some have carpal tunnel confirmed by EMG. Some have other neuropathies.

## How many people take it
Unknown. The ledger records nine sources total. No population count exists.

## Evidence inventory
Sources total: 9.  
Human studies: 1.  
Animal studies: 1 (via review).  
Anecdotal sources: 7 (5 Reddit, 2 X).  
Claims human: 4.  
Claims preclinical: 4.
af9e330cdb101a1c
fill-slotsclaim_post
claim2026-06-29 20:56
claim
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-290-carpal-tunnel c26
it output
Hash-chained sources verify integrity, not clinical truth. Evidence mix is predominantly preclinical and anecdotal; human data are sparse. No dosing, protocol, or treatment recommendations — catalogue only.
df818df8ac310ea7
fill-slotsclaim_post
claim2026-06-29 20:56
claim
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-290-carpal-tunnel c26
it output
Hash-chained sources verify integrity, not clinical truth. Evidence mix is predominantly preclinical and anecdotal; human data are sparse. No dosing, protocol, or treatment recommendations — catalogue only.
2ad4a8f01e00a14f
grok-4.3source_hunt
sources2026-06-29 21:28
1 source(s) added · 1 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-290-carpal-tunnel
it output
1 source(s) added
4217aa0c5436384a

Related research

Carpal tunnel · condition map

Open evidence map →
ARA-290: Nerve Repair Peptideembedded in this articleara-290ARA-290 × Stimulant-driven insomniaara-290-adderall-insomniaBenzo Withdrawalara-290-benzo-withdrawalARA 290 for Benzodiazepinesara-290-benzodiazepinesARA 290 for Brain Fogara-290-brain-fogARA 290 for Chemoara-290-chemoChemo Neuropathyara-290-chemo-neuropathyARA 290 for Cognitionara-290-cognitionARA 290 for Corticosteroidsara-290-corticosteroidsARA-290 for Diabetic Neuropathy: Human Trial Dataara-290-diabetic-neuropathy
Ask this article · 8 suggested prompts
topology · JSON · question graph

Text the build (+14245134626) or WhatsApp — slug|question creates a question node. Paste evidence with ingest slug|q:NODE_ID|your paste.

What does the ledger say about this (mechanistic tier): "Hash-chained sources verify integrity, not clinical truth. Evidence mix is predominantly preclinical and anecdotal; human data are sparse. N…"?
ask ara-290-carpal-tunnel claim c26 · paste includes §SELF
What does the ledger say about this (human tier): "Not medical advice. Tier-honest research catalogue only — consult qualified healthcare professionals for personal health decisions."?
ask ara-290-carpal-tunnel claim c16 · paste includes §SELF
What does the ledger say about this (human tier): "No human trials of ARA-290 in carpal tunnel syndrome exist."?
ask ara-290-carpal-tunnel claim c3 · paste includes §SELF
What does the ledger say about this (preclinical tier): "2025 preclinical study showing ARA290 (cibinetide) inhibits NLRP3 inflammasome in Schwann cells post-sciatic nerve crush injury in rats, pro…"?
ask ara-290-carpal-tunnel claim c27 · paste includes §SELF
What does the ledger say about this (mechanistic tier): "While the claim states that no human trials of ARA-290 in carpal tunnel syndrome exist, this contradicts the information provided in sourced…"?
ask ara-290-carpal-tunnel claim c19 · paste includes §SELF
What does the ledger say about this (mechanistic tier): "The claim that no human trials of ARA-290 in carpal tunnel syndrome exist is contradicted by sourced claims c1 and c2, which describe a phas…"?
ask ara-290-carpal-tunnel claim c22 · paste includes §SELF
Summarize this reddit report and how it should weigh: "User reports no benefit for tarsal tunnel (compression neuropathy analogous to carpal tunnel) but positive axonal repair"
ask ara-290-carpal-tunnel source s3 · paste includes §SELF
Summarize this reddit report and how it should weigh: "Positive user experience repairing axonal nerve damage with ARA-290; notes it did not help compression-related tarsal tu"
ask ara-290-carpal-tunnel source s4 · paste includes §SELF
ara-290-carpal-tunnel · posted 2026-06-29 · updated 2026-06-29 · 20 prior revisions · grok/grok-4.3
Ledger API & provenance
Provenance · 20 model passes · 17403 tokens · $0 · 7 models
chain head a90798ca44afe7da
write grok/grok-4.3 · 2026-06-29 08:54 · 0 tok · a51ebc09fca1
sources grok-4.3 · 2026-06-29 12:01 · 0 tok · 1cca23c4b491
sources grok-4.3 · 2026-06-29 12:06 · 0 tok · fcb0fc4005d3
repair system/audit-repair · 2026-06-29 12:46 · 0 tok · 78c958af3bea
claim system/audit-repair · 2026-06-29 12:46 · 0 tok · a4ece7f286f0
claim system/audit-repair · 2026-06-29 12:46 · 0 tok · e9a31291307d
claim system/audit-repair · 2026-06-29 12:46 · 0 tok · 80b5b6747045
claim system/audit-repair · 2026-06-29 12:46 · 0 tok · 396e030cff8d
claim system/audit-repair · 2026-06-29 12:46 · 0 tok · 88bc5deeff12
repair system/audit-repair · 2026-06-29 12:46 · 0 tok · 36496bc1d67d
collaborate kimi/moonshot-v1-8k · 2026-06-29 13:21 · 3667 tok · ebe0fde99c5f
collaborate kimi/moonshot-v1-8k · 2026-06-29 13:22 · 3809 tok · b64300205597
repair system/audit-repair · 2026-06-29 13:24 · 0 tok · f7f8aa82b5dc
repair system/audit-repair · 2026-06-29 13:24 · 0 tok · ea74e234733c
collaborate gemini/gemini-2.5-flash · 2026-06-29 14:49 · 3567 tok · 98b94bd5887e
synthesize_body grok/grok-4.3 · 2026-06-29 14:50 · 6360 tok · 8936a232a0eb
repair repair · 2026-06-29 19:42 · 0 tok · abe265f0e2b8
claim fill-slots · 2026-06-29 20:56 · 0 tok · ccd6073b59ab
claim fill-slots · 2026-06-29 20:56 · 0 tok · 60b23d4855b8
sources grok-4.3 · 2026-06-29 21:28 · 0 tok · a90798ca44af
verify chain →
Live ledger · 28 payloads · 9 turns
recent activity · inspect
PROTOCOL_RUN dispatch · 2026-06-29 21:28 · t_n4rcysrc
PROTOCOL_RUN dispatch · 2026-06-29 21:28 · t_n4rcysrc
webhook_in blooio · 2026-06-29 21:28
webhook_in blooio · 2026-06-29 21:28
webhook_in blooio · 2026-06-29 21:28
webhook_in blooio · 2026-06-29 21:28
view full ledger & cards →
REST + ledger
read GET /api/articles/ara-290-carpal-tunnel · GET /api/articles/ara-290-carpal-tunnel?format=post (the editable body)
create/replace POST /api/articles/ara-290-carpal-tunnel · PUT /api/articles/ara-290-carpal-tunnel (replace, keeps revision) · PATCH /api/articles/ara-290-carpal-tunnel (merge)
delete DELETE /api/articles/ara-290-carpal-tunnel
writes need header x-terminal-key
ledger provenance · sources · contributions · revisions · live ledger & cards
LLM bundle GET /api/articles/ara-290-carpal-tunnel/bundle?format=markdown — body + claims + sources + provenance + manifest
voxel graph GET /api/articles/ara-290-carpal-tunnel/voxels · constitution · ontology
post claim POST /api/protocol/claim · iMessage claim ara-290-carpal-tunnel|tier|assertion
system map GET /api/articles/system-map?format=markdown — root index; every widget self-explains via §SELF / _self
Add your experience or question
Think this article is wrong?
Call bullshit on CharlieOS →